No Correlation between Plasma NMDA-Related Glutamatergic Amino Acid Levels and Cognitive Function in Medicated Patients with Schizophrenia

Abstract

Objective:

Disrupted glutamatergic neurotransmission and cognitive functions are key components in the pathophysiology of schizophrenia. Changes in levels of serum/plasma glutamatergic amino acids, such as glutamate, glycine, and L- and D-serine may be possible clinical markers. Following our recent findings that peripheral blood levels of endogenous glycine, alanine, and especially D-serine may reflect the degree/change in symptoms in schizophrenia, here we investigated whether these plasma amino acid levels may also reflect the status of cognitive functions in schizophrenia.

Methods:

One hundred eight Japanese patients with schizophrenia were evaluated with cognitive assessment batteries at the time that plasma glutamatergic amino acid levels were measured using high-performance liquid chromatography. For analyzing cognitive functions, batteries for reflection prefrontal cortex cognitive functions, verbal fluency tests, the Stroop test, and the digit span forward and backward tests were administered.

Results:

Results failed to show a relationship between any plasma glutamatergic amino acid level and cognitive batteries.

Conclusions:

Our results suggest that plasma glutamatergic amino acid levels may be significant biological markers that reflect the condition or a dramatic change at the time of testing, especially in severely affected patients, but they do not reflect cognitive function.

Keywords

cognitive function glutamate serine plasma schizophrenia

Get full access to this article

View all access options for this article.

References

Javitt

Zukin

. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991;148:1301–1308.

Ohnuma

Suzuki

Arai

. Hypothesis: Minimal changes in neural transmission in schizophrenia: Decreased glutamatergic and GABAergic functions in the prefrontal cortex. Progress in Neuropsychopharmacology and Biological Psychiatry 2005;29(6):889–894.

Olney

Farber

. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995;52(12):998–1007.

Andersen

Pouzet

. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004; 29(6):1080–1090.

Hashimoto

Fujita

Ishima

Chaki

Iyo

. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. The Journal of European College of Neuropsychopharmacology 2008;18(6):414–421.

Javitt

. Treatment of negative and cognitive symptoms. Current Psychiatry Reports 1999;1(1):25–30.

Tamminga

. The neurobiology of cognition in schizophrenia. The Journal of Clinical Psychiatry 2006;67(9):e11.

Hashimoto

Fukushima

Shimizu

Komatsu

Watanabe

Shinoda

. Decreased serum levels of d-serine in patients with schizophrenia: Evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 2003;60(6):572–576.

Neeman

Blanaru

Bloch

Kremer

Ermilov

Javitt

. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. The American Journal of Psychiatry 2005;162(9):1738–1740.

10.

Hatano

Ohnuma

Sakai

Shibata

Maeshima

Hanzawa

. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve—Results from the Juntendo University Schizophrenia Projects (JUSP). Psychiatry Research 2010;177(1–2):27–31.

11.

Maeshima

Ohnuma

Sakai

Shibata

Baba

Ihara

. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia—Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2007;31(7): 1410–1418.

12.

Ohnuma

Sakai

Maeshima

Hatano

Hanzawa

Abe

. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2008;32(8):1905–1912.

13.

Heresco-Levy

Bar

Levin

Ermilov

Ebstein

Javitt

. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophrenia Research 2007;91(1–3):14–21.

14.

Tsai

Yang

Chung

Lange

Coyle

. d-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 1998;44(11): 1081–1089.

15.

Tsai

Yang

Chang

Chong

. d-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2006;59(3):230–234.

16.

Bauer

Hamacher

Broer

Pauleit

Palm

Zilles

. Preferred stereo-selective brain uptake of D-serine—A modulator of glutamatergic neurotransmission. Nuclear Medicine and Biology 2005;32(8):793–797.

17.

Nishikawa

. Metabolism and functional roles of endogenous D-serine in mammalian brains. Biological and Pharmaceutical Bulletin 2005;28(9):1561–1565.

18.

Hashimoto

Shimizu

Iyo

. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Current Psychiatry Review 2005;1:151–163.

19.

First

Spitzer

Gibbon

Williams

JBW

. Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute, New York, 1995.

20.

Overall

JE GO

. The Brief Psychiatry Rating Scale. Psychological Report 1962;10:99–812.

21.

Bech

Kastrup

Rafaelsen

. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatrica Scandinavica 1986;326:1–37.

22.

Davis

. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976;33(7):858–861.

23.

Tran

Hamilton

Kuntz

Potvin

Andersen

Beasley

Jr. . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997;17(5):407–418.

24.

Higa

Ohnuma

Maeshima

Hatano

Hanzawa

Shibata

. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP). Neuroscience Letters 2010;469(1):55–59.

25.

Fletcher

Frith

Grasby

Friston

Dolan

. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. The Journal of Neuroscience 1996;16(21):7055–7062.

26.

Gaillard

Hertz-Pannier

Mott

Barnett

LeBihan

Theodore

. Functional anatomy of cognitive development: Fmri of verbal fluency in children and adults. Neurology 2000;54(1):180–185.

27.

Cohen

Servan-Schreiber

. Context, cortex, and dopamine: A connectionist approach to behavior and biology in schizophrenia. Psychological Review 1992;99(1):45–77.

28.

Goethals

Audenaert

Jacobs

Lannoo

Van de Wiele

Ham

Otte

. Cognitive neuroactivation using SPECT and the Stroop Colored Word Test in patients with diffuse brain injury. Journal of Neurotrauma 2004;21(8): 1059–1069.

29.

Minatogawa-Chang

Schaufelberger

Ayres

Duran

Gutt

Murray

. Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis. Schizophrenia Research 2009;113(2–3):200–209.

30.

Stone

Gabrieli

Stebbins

Sullivan

. Working and strategic memory deficits in schizophrenia. Neuropsychology 1998;12(2):278–288.

31.

Matsuoka

Uno

Kasai

Koyama

Kim

. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry and Clinical Neuroscience 2006;60(3):332–339.

32.

Carter

Mintun

Cohen

. Interference and facilitation effects during selective attention: An H215O PET study of Stroop task performance. Neuroimage 1995;2(4):264–272.

33.

Ohnuma

Arai

. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2011;35(1):29–39.

34.

Mahurin

Velligan

Miller

. Executive-frontal lobe cognitive dysfunction in schizophrenia: A symptom subtype analysis. Psychiatry Research 1998;79(2): 139–149.

35.

Savilla

Kettler

Galletly

. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. The Australian and New Zealand Journal of Psychiatry 2008;42(6):496–504.

36.

Conklin

Curtis

Katsanis

Iacono

. Verbal working memory impairment in schizophrenia patients and their first-degree relatives: Evidence from the digit span task. American Journal of Psychiatry 2000;157(2):275–277.

37.

Garlinghouse

Roth

Isquith

Flashman

Saykin

. Subjective rating of working memory is associated with frontal lobe volume in schizophrenia. Schizophrenia Research 2010;120(1–3):71–75.

38.

Twamley

Palmer

Jeste

Taylor

Heaton

. Transient and executive function working memory in schizophrenia. Schizophrenia Research 2006;87(1–3): 185–190.

39.

Nakano

Baba

Maeshima

Kitajima

Sakai

Baba

. Executive dysfunction in medicated, remitted state of major depression. Journal of Affective Disorders 2008;111(1):46–51.

40.

Kantrowitz

Malhotra

Cornblatt

Silipo

Balla

Suckow

. High dose d-serine in the treatment of schizophrenia. Schizophrenia Research 2010;121(1–3):125–130.

41.

Shad

Tamminga

Cullum

Haas

Keshavan

. Insight and frontal cortical function in schizophrenia: A review. Schizophrenia Research 2006;86(1–3): 54–70.

42.

Carter

Barch

Bullmore

Breiling

Buchanan

Butler

. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biological Psychiatry 2011;70(1):7–12.